MedPath

Transversalis Fascia Plane Blocks for Analgesia Post-cesarean Delivery

Phase 2
Completed
Conditions
Cesarean Delivery
Interventions
Device: ultrasound-guided nerve block
Drug: Saline
Drug: Bupivacaine-epinephrine
Registration Number
NCT03236324
Lead Sponsor
University of Calgary
Brief Summary

The aim of this study is to assess the efficacy of a bilateral TFP block in parturients undergoing cesarean delivery (CD) by evaluating postoperative opioid consumption and numeric rated pain scores in two groups (TFP block with saline (control) and TFP block with local anesthetic (treatment)). Women (American Society of Anesthesiologists physical status Class 1-3) at term gestation with singleton pregnancies undergoing an elective CD under spinal anesthesia at the South Health Campus will be consented to participate in the study. Patients will be randomly assigned using a computer-generated table of random numbers to two groups. Group allocations will be concealed. All patients will receive spinal anesthesia with spinal Morphine according to our institutional protocol. At the end of surgery, randomized patients will receive either ultrasound-guided bilateral TFP blocks with 0.25% bupivacaine with 2.5 mcg/ml epinephrine 40 ml total or maximum 2.5 mg/kg (Group 1) or 40 mL saline (Group 2) by 2 anesthesiologists experienced in performing this block.

Detailed Description

Caesarean delivery (CD) is one of the most commonly performed surgical procedures with an estimated annual frequency of 27% in Alberta between 2007-2011. Poorly controlled postsurgical pain is associated with an increase in morbidity. Untreated or undertreated pain can lead to respiratory infections secondary to splinting and shallow breathing. Excessive pain also reduces and delays ambulation, which can lead to both an increase in the incidence of deep vein thrombosis (DVT) and delay recovery and readiness for discharge. Poorly controlled pain may also lead to the development of chronic postsurgical pain. The optimal form of postoperative analgesia following CD is not known. Most postoperative analgesic protocols for CD, despite being multimodal in nature, rely heavily on opioid medications both orally and intrathecally for analgesia. These medications, however, are not without serious side effects such as nausea, vomiting, sedation, addiction or dependence, and respiratory depression as well as expression in breast milk which may put infants at risk of side effects as well. Thus, an effective alternative analgesic modality analgesia in these patients which produces both improved pain control and reduced side effects is desired. The TFP block represents a promising alternative, which may fulfill this role in complementing multimodal analgesia for patients undergoing CD and reducing opioid administration.

This project aims to elucidate information regarding alternative interventions for postoperative analgesia following CD. While the most common analgesic regimen of intrathecal and oral opioids, acetaminophen, and NSAIDS for postoperative analgesia is effective, it is not appropriate for all patients. For those who cannot receive intrathecal opioids (e.g. those with allergies to opioid medications, or those who are undergoing CD under general anesthetic), alternative analgesic modalities are important to provide adequate multimodal analgesia and minimize side effects of each of the analgesic medications. Additionally, this aforementioned common analgesic pathway may itself be further optimized through the addition of new analgesic techniques. The Transversalis Fascia Plane (TFP) block is a nerve block, which could potentially target nerves responsible for transmitting pain following CD, and represents a promising novel analgesic modality.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
106
Inclusion Criteria
  • elective Cesarean delivery with spinal anesthesia at South Health Campus
  • term gestation with a singleton pregnancy
  • American Society of Anesthesiologists' (ASA) physical status Class 1-3
Read More
Exclusion Criteria
  • language barrier
  • body mass index (BMI) > 40 kg/m2
  • multiple gestations
  • chronic pain
  • opioid use
  • substance abuse
  • allergies to study medication
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
TFP block with salineultrasound-guided nerve blockPlacebo bilateral ultrasound-guided nerve block \[transversalis fascia plane (TFP) block\] with 40 mL saline, single shot
TFP block with local anestheticultrasound-guided nerve blockExperimental bilateral ultrasound-guided nerve block \[transversalis fascia plane (TFP) block\] with local anesthesic of Bupivacaine-epinephrine \[0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)\], single shot
TFP block with salineSalinePlacebo bilateral ultrasound-guided nerve block \[transversalis fascia plane (TFP) block\] with 40 mL saline, single shot
TFP block with local anestheticBupivacaine-epinephrineExperimental bilateral ultrasound-guided nerve block \[transversalis fascia plane (TFP) block\] with local anesthesic of Bupivacaine-epinephrine \[0.25% bupivacaine with 2.5 mcg/mL epinephrine 40 mL (maximum 2.5 mg/kg)\], single shot
Primary Outcome Measures
NameTimeMethod
Postoperative opioid consumption24 hours

24-hour postoperative opioid consumption presented in morphine equivalents

Secondary Outcome Measures
NameTimeMethod
Patient satisfaction48 hours

Evaluate patient satisfaction of postoperative pain relief at time of discharge

Numeric rating scale pain scoresup to 48 hours

Pain scores to be assessed at rest and movement 6, 12, 18, 24 and 48 hours post-Cesarean delivery

Opioid side effects48 hours

Evaluate incidence of nausea, vomiting, pruritus, sedation after Cesarean delivery

Quality of recovery scoresup to 48 hours

Quality of recovery (QoR-15) scores acquired preoperatively, 24 hour and 48 hours after Cesarean delivery

Time to first analgesia48 hours

Time to request of first analgesia after Cesarean delivery

Post-discharge numeric rating pain scale scoresup to 60 days

Evaluate pain scores at 30 days and 60 days after Cesarean delivery

Trial Locations

Locations (1)

South Health Campus

🇨🇦

Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath